Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 696 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cellcept Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

NCT01203722
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Fludarabine, Cytoxan, Total Body Irradiation, Allogeneic Blood or Marrow Transplant, Peripheral Blood Stem Cell Transplant, Mycophenolate Mofetil, Sirolimus, Tacrolimus
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Nov 13, 2026, 2:04 AM EST
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 3 Interventional Results available

Methotrexate and Mycophenolate Mofetil for UVEITIS

NCT01829295
View directory record Official record
Conditions
Uveitis
Interventions
Mycophenolate mofetil, Methotrexate, Prednisone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Nov 13, 2026, 2:04 AM EST
Withdrawn Not applicable Interventional

Myfortic in High MELD Liver Transplantation

NCT01807767
View directory record Official record
Conditions
High Model for End-Stage Liver Disease (MELD) Score
Interventions
Everolimus, Myfortic and Tacrolimus, Myfortic and Tacrolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 13, 2026, 2:04 AM EST
Completed Not applicable Interventional Results available

Using mTOR Inhibitors in the Prevention of BK Nephropathy

NCT01649609
View directory record Official record
Conditions
BK Viremia, BK Nephropathy
Interventions
Tacrolimus, Mycophenolate acid, Sirolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 2 Interventional Results available

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

NCT02918292
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 13, 2026, 2:04 AM EST
Terminated Phase 1 Interventional

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

NCT00354419
View directory record Official record
Conditions
Aplastic Anemia
Interventions
total-body irradiation, cyclophosphamide, anti-thymocyte globulin, cyclosporine, umbilical cord blood transplantation, mycophenolate mofetil, bone marrow aspiration, DNA analysis, filgrastim
Radiation · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Nov 13, 2026, 2:04 AM EST
Suspended Phase 2 Interventional

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

NCT06680661
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 13, 2026, 2:04 AM EST
Completed Not applicable Interventional

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

NCT00010361
View directory record Official record
Conditions
Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Interventions
cyclosporine, fludarabine, mycophenolate mofetil
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Nov 13, 2026, 2:04 AM EST
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 13, 2026, 2:04 AM EST
Terminated Phase 1 Interventional

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

NCT01369628
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Nov 13, 2026, 2:04 AM EST
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT00008177
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions
iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 3 Interventional Results available

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

NCT01187953
View directory record Official record
Conditions
Renal Failure
Interventions
Prograf (tacrolimus), LCP-Tacro
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

NCT01903798
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Mycophenolate mofetil, Prednisolone, Rilonacept
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Long Beach, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 4 Interventional Results available

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

NCT00771745
View directory record Official record
Conditions
Renal Transplant Rejection, Transplants and Implants
Interventions
Thymoglobulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 2 Interventional Results available

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

NCT01807611
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide, Thiotepa, Melphalan, HPC,A Infusion, TC-NK Infusion, G-CSF, Mesna, CliniMACS, Mycophenolate mofetil
Radiation · Drug · Biological + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Nov 13, 2026, 2:04 AM EST
Withdrawn Phase 2Phase 3 Interventional

Uterine Transplant in Absolute Uterine Infertility (AUIF)

NCT02741102
View directory record Official record
Conditions
Female Infertility
Interventions
Uterine Transplant
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 1Phase 2 Interventional Results available

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

NCT00630253
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

NCT01350245
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Plasma Cell Neoplasms, Lymphoma, Hodgkin's Disease, Aplastic Anemia
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Mycophenolate Mofetil (MMF), Tacrolimus, Hematopoietic stem cell transplantation (HSCT)
Radiation · Biological · Drug + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 13, 2026, 2:04 AM EST
Terminated Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00119366
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
16 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Nov 13, 2026, 2:04 AM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Nov 13, 2026, 2:04 AM EST